PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.79%
Cash & equivalents declining -24.79% while Medical - Pharmaceuticals shows -6.42% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-24.79%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -5.60%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-2.78%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-2.34%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-0.84%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-9.64%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -0.71%. Joel Greenblatt sees a potential liquidity edge if well allocated.
4.17%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.80%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-11.54%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-11.54%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
1.04%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-1.04%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1.04%
Above 1.5x Medical - Pharmaceuticals median of 0.05%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.76%
1.25-1.5x Medical - Pharmaceuticals median of 2.75%. Mohnish Pabrai notes above-average expansions in non-current assets.
50.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
-0.61%
1.25-1.5x Medical - Pharmaceuticals median of -0.46%. Mohnish Pabrai might see above-average growth. Check if financed sensibly.
-2.08%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
-28.93%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-27.31%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-0.66%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-3.20%
Below half Medical - Pharmaceuticals median of 1.68%. Joel Greenblatt sees more conservative short-term leverage than peers.
-8.02%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.41%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-5.59%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-3.60%
Below half Medical - Pharmaceuticals median of 1.89%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
4.23%
Below half Medical - Pharmaceuticals median of -2.23%. Jim Chanos suspects poor profitability or large dividend drains.
39.39%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
3.83%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
-0.61%
≥ 1.5x Medical - Pharmaceuticals median of -0.27%. Joel Greenblatt sees more aggressive expansions than peers.
1.04%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-6.07%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
108.77%
Above 1.5x Medical - Pharmaceuticals median 5.60%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.